The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
Open accessAbstract
A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid beta-peptide (A beta). A beta oligomeric ligands (also known as ADDLs) are known to be potent inhibitors of hippocampal long-term potentiation, which is a paradigm for synaptic plasticity, and have been linked to synapse loss and reversible memory failure in transgenic mouse AD models. If such oligomers were to build up in human brain, their neurological impact could provide the missing link that accounts for the poor correlation between AD dementia and amyloid plaques. This article, using antibodies raised against synthetic A beta oligomers, verifies the predicted accumulation of soluble oligomers in AD frontal cortex. Oligomers in AD reach levels up to 70-fold over control brains. Brain-derived and synthetic oligomers show structural equivalence with respect to mass, isoelectric point, and recognition by conformation-sensitive antibodies. Both oligomers, moreover, exhibit the same striking patterns of attachment to cultured hippocampal neurons, binding on dendrite surfaces in small clusters with ligand-like specificity. Binding assays using solubilized membranes show oligomers to be high-affinity ligands for a small number of nonabundant proteins. Current results confirm the prediction that soluble oligomeric A beta ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [11]
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [18]
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [8]
In the citing paper
“Dot immunoblots of soluble extracts from human brain show major increases in oligomers in AD-affected tissue (Gong et al., 2003; Kayed et al., 2003; Lambert et al., 2001).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“as have the related predictions that oligomers cause dysfunctional trafficking of ionotropic glutamate receptors and metabotropic glutamate receptors (Gong et al., 2003; Lacor et al., 2004).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Cultured hippocampal neurons incubated with brain-derived oligomers show patterns that recapitulate the in situ distribution (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
In the citing paper
“Because Arc is an actin binding protein, its aberrant expression was predicted to disrupt receptor trafficking (Lacor et al., 2004), which could consequently disrupt plasticity (Gong et al., 2003).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Gong et al., 2003
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Lipid rafts and signal transduction
Simons, K., & Toomre, D. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 5,371
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Research works printed but not linked: 2
- Terry R. D. (1999) in Alzheimer Disease eds. Terry R. D. Katzman R. Bick K. L. & Sisodia S. S. (Lippincott Williams & Wilkins Philadelphia) pp. 187-206.
- Chang L. Gong Y. Bakhos L. Yu J. Venton D. L. & Klein W. L. (2003) J. Mol. Neurosci. in press.
Cited by
Sorted by citations
Items 201–300 of 1,000
Spatial relationship between synapse loss and β‐amyloid deposition in Tg2576 mice
Dong, H., Martin, M. V., Chambers, S., & Csernansky, J. G. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.21176 · Cited by 149
Diomede, L., Rigacci, S., Romeo, M., Stefani, M., & Salmona, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058893 · Cited by 151
Schützmann, M. P., Hasecke, F., Bachmann, S., Zielinski, M., Hänsch, S., Schroeder, G. F., Zempel, H., & Hoyer, W. (2021) · Nature Communications · doi:10.1038/s41467-021-24900-4 · Cited by 152
Frydman‐Marom, A., Rechter, M., Shefler, I., Bram, Y., Shalev, D. E., & Gazit, E. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200802123 · Cited by 145
Bieschke, J., Zhang, Q., Powers, E. T., Lerner, R. A., & Kelly, J. W. (2005) · Biochemistry · doi:10.1021/bi0501030 · Cited by 145
Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
Swerdlow, R. H. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.021 · Cited by 154
Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?
Li, X., Masliah, E., Reixach, N., & Buxbaum, J. N. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2417-11.2011 · Cited by 147
Klein, W. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129039 · Cited by 145
Self-citationNicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease
Yao, Z., Yang, W., Gao, Z., & Jia, P. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.03.027 · Cited by 140
Chaperone signalling complexes in Alzheimer's disease
Koren, J., Jinwal, U. K., Lee, D. C., Jones, J. R., Shults, C. L., Johnson, A. G., Anderson, L. J., & Dickey, C. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00557.x · Cited by 141
Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly
Ohnishi, T., Yanazawa, M., Sasahara, T., Kitamura, Y., Hiroaki, H., Fukazawa, Y., Kii, I., Nishiyama, T., Kakita, A., Takeda, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421182112 · Cited by 141
Meilandt, W. J., Cissé, M., Ho, K., Wu, T. Z., Esposito, L., Scearce-Levie, K. A., Cheng, I. H.-J., Yu, G.-Q., & Mucke, L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2984-08.2009 · Cited by 144
Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease
Varvel, N. H., Bhaskar, K., Patil, A. R., Pimplikar, S. W., Herrup, K., & Lamb, B. T. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2441-08.2008 · Cited by 141
Gralle, M., Caarls, M. B., & Wouters, F. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808755200 · Cited by 148
Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Atamna, H., & Kumar, R. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100414 · Cited by 142
Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
Boche, D., Denham, N., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0719-5 · Cited by 135
The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity
Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013) · Metallomics · doi:10.1039/c3mt00161j · Cited by 135
Cholesterol in Alzheimers Disease: Unresolved Questions
Stefani, M., & Liguri, G. (2009) · Current Alzheimer Research · doi:10.2174/156720509787313899 · Cited by 136
Lahiri, D. K., Chen, D., Maloney, B., Holloway, H. W., Yu, Q.-S., Utsuki, T., Giordano, T., Sambamurti, K., & Greig, N. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112102 · Cited by 134
Zerbinatti, C. V., Wozniak, D. F., Cirrito, J., Cam, J. A., Osaka, H., Bales, K. R., Zhuo, M., Paul, S. M., Holtzman, D. M., & Bu, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305803101 · Cited by 133
Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors
Guglielmotto, M. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2010 · Cited by 135
Alzheimer's disease: insights from Drosophila melanogaster models
Moloney, A. M., Sattelle, D. B., Lomas, D. A., & Crowther, D. C. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.11.004 · Cited by 135
Rinauro, D. J., Chiti, F., Vendruscolo, M., & Limbocker, R. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00651-2 · Cited by 138
A Role for Calcineurin in Alzheimers Disease
Reese, L. C., & Taglialatela, G. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376316 · Cited by 132
Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. G. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-40 · Cited by 138
Maloney, M. T., Minamide, L. S., Kinley, A. W., Boyle, J. A., & Bamburg, J. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3711-05.2005 · Cited by 140
Hirohata, M., Ono, K., Naiki, H., & Yamada, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.004 · Cited by 132
Extending the PRIME model for protein aggregation to all 20 amino acids
Cheon, M., Chang, I., & Hall, C. K. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22817 · Cited by 135
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models
COLE, G. M., MORIHARA, T., LIM, G. P., YANG, F., BEGUM, A., & FRAUTSCHY, S. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.005 · Cited by 129
Nirmalraj, P. N., List, J., Battacharya, S., Howe, G., Xu, L., Thompson, D., & Mayer, M. (2020) · Science Advances · doi:10.1126/sciadv.aaz6014 · Cited by 131
Butterfield, D. A., & Bush, A. I. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.027 · Cited by 129
ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing
Satoh, K., Abe-Dohmae, S., Yokoyama, S., St George-Hyslop, P., & Fraser, P. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655076 · Cited by 128
Narayanan, S., & Reif, B. (2005) · Biochemistry · doi:10.1021/bi048264b · Cited by 128
Treatment Strategies Targeting Amyloid -ProteinPreprint
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 131
Nishitsuji, K., Tomiyama, T., Ishibashi, K., Ito, K., Teraoka, R., Lambert, M. P., Klein, W. L., & Mori, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080480 · Cited by 127
Self-citationPlasmonic nanoparticles and their analytical applications: A review
Boken, J., Khurana, P., Thatai, S., Kumar, D., & Prasad, S. (2017) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2017.1312427 · Cited by 129
Down syndrome and beta-amyloid deposition
Head, E., & Lott, I. T. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200404000-00003 · Cited by 129
Soluble Amyloid-beta Aggregates from Human Alzheimer’s Disease Brains
Esparza, T. J., Wildburger, N. C., Jiang, H., Gangolli, M., Cairns, N. J., Bateman, R. J., & Brody, D. L. (2016) · Scientific Reports · doi:10.1038/srep38187 · Cited by 127
Memantine lowers amyloid‐β peptide levels in neuronal cultures and in APP/PS1 transgenic mice
Alley, G. M., Bailey, J. A., Chen, D., Ray, B., Puli, L., Tanila, H., Banerjee, P., & Lahiri, D. K. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22172 · Cited by 126
Alzheimer’s β-peptide oligomer formation at physiologic concentrations
LeVine, H. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.08.014 · Cited by 125
Molecular understanding of a potential functional link between antimicrobial and amyloid peptides
Zhang, M., Zhao, J., & Zheng, J. (2014) · Soft Matter · doi:10.1039/c4sm00907j · Cited by 123
Yang, T., Hong, S. Y., O’Malley, T. T., Sperling, R. A., Walsh, D. M., & Selkoe, D. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.005 · Cited by 122
Felice, F. G. D., & Lourenco, M. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00094 · Cited by 122
The case for soluble Aβ oligomers as a drug target in Alzheimer's disease
Hefti, F. F., Goure, W. F., Jerecìć, J., Iverson, K. S., Walicke, P. A., & Krafft, G. A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.002 · Cited by 122
Self-citationPhotophysical study of Thioflavin T as fluorescence marker of amyloid fibrils
Freire, S., de Araujo, M. H., Al‐Soufi, W., & Novo, M. (2014) · Dyes and Pigments · doi:10.1016/j.dyepig.2014.05.004 · Cited by 119
Echeverrı́a, V., Clerman, A., & Doré, S. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04427.x · Cited by 122
Zhang, Y., Rempel, D. L., Zhang, J., Sharma, A. K., Mirica, L. M., & Gross, M. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309175110 · Cited by 118
Impact of amyloid imaging on drug development in Alzheimer's disease
Mathis, C. A., Lopresti, B. J., & Klunk, W. E. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.015 · Cited by 121
Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348300 · Cited by 124
Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O., & Tabaton, M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.01.021 · Cited by 119
Williams, C., Mehrian Shai, R., Wu, Y., Hsu, Y.-H., Sitzer, T., Spann, B., McCleary, C., Mo, Y., & Miller, C. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004936 · Cited by 116
Okada, T., Ikeda, K., Wakabayashi, M., Ogawa, M., & Matsuzaki, K. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.072 · Cited by 116
β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension
Gentile, M. T., Poulet, R., Pardo, A. D., Cifelli, G., Maffei, A., Vecchione, C., Passarelli, F., Landolfi, A., Carullo, P., & Lembo, G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.005 · Cited by 118
Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases
Forloni, G., Artuso, V., Vitola, P. L., & Balducci, C. (2016) · Movement Disorders · doi:10.1002/mds.26624 · Cited by 116
Penke, B., Szűcs, M., & Bogár, F. (2020) · Molecules · doi:10.3390/molecules25071659 · Cited by 119
Amyloid-β Production: Major Link Between Oxidative Stress and BACE1
Tamagno, E., Guglielmotto, M., Monteleone, D., & Tabaton, M. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9283-6 · Cited by 117
Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivo
Klyubin, I. V., Walsh, D. M., Cullen, W. K., Fadeeva, J. V., Anwyl, R., Selkoe, D. J., & Rowan, M. J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03389.x · Cited by 121
Okada, T., Wakabayashi, M., Ikeda, K., & Matsuzaki, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.069 · Cited by 116
β-Amyloid Modulation of Synaptic Transmission and Plasticity
Venkitaramani, D. V., Chin, J., Netzer, W. J., Gouras, G. K., Lesné, S., Malinow, R., & Lombroso, P. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3478-07.2007 · Cited by 118
Picone, P., Nuzzo, D., Caruana, L., Messina, E., Barera, A., Vasto, S., & Carlo, M. D. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.017 · Cited by 116
Dong, H., Csernansky, C. A., Martin, M. V., Bertchume, A., Vallera, D., & Csernansky, J. G. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2230-6 · Cited by 116
Bell, K. A., O’Riordan, K. J., Sweatt, J. D., & Dineley, K. T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02722.x · Cited by 117
Abdul, H. M., Rukhsana Sultana, A., Keller, J. N., Clair, D. K. S., Markesbery, W. R., & Butterfield, D. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03647.x · Cited by 114
Rana, M., & Sharma, A. K. (2018) · Metallomics · doi:10.1039/c8mt00203g · Cited by 116
Plaque-associated lipids in Alzheimer’s diseased brain tissue visualized by nonlinear microscopy
Kiškis, J., Fink, H., Nyberg, L. K., Thyr, J., Li, J., & Enejder, A. M. K. (2015) · Scientific Reports · doi:10.1038/srep13489 · Cited by 117
Alzheimer’s Disease: Etiology, Neuropathology and Pathogenesis
Sheppard, O., & Coleman, M. P. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch1 · Cited by 127
Cofilin-mediated neurodegeneration in alzheimer’s disease and other amyloidopathies
Maloney, M. T., & Bamburg, J. R. (2007) · Molecular Neurobiology · doi:10.1007/bf02700622 · Cited by 115
Aβ-globulomers are formed independently of the fibril pathway
Gellermann, G. P., Byrnes, H., Striebinger, A., Ullrich, K., Mueller, R., Hillen, H., & Barghorn, S. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.01.010 · Cited by 117
Aryl sulfones: a new class of γ-secretase inhibitors
Teall, M. R., Oakley, P. J., Harrison, T., Shaw, D., Kay, E. R., Elliott, J. M., Gerhard, U., Castro, J. L., Shearman, M. S., Ball, R. G., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.017 · Cited by 112
ADDLs and the signaling web that leads to Alzheimer’s disease
Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 113
Self-citationHeparan sulfate mediates amyloid-beta internalization and cytotoxicity
Sandwall, E., O'Callaghan, P. W., Zhang, X., Lindahl, U., Lannfelt, L., & Li, J. (2010) · Glycobiology · doi:10.1093/glycob/cwp205 · Cited by 116
Yun, S., Urbanc, B., Cruz, L., Bitan, G., Teplow, D. B., & Stanley, E. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.097766 · Cited by 111
The Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease
Wang, Z.-X., Tan, L., Liu, J., & Yu, J.-T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9143-0 · Cited by 110
Neuroregeneration in neurodegenerative disorders
Enciu, A., Nicolescu, M. I., Manole, C. G., Muresanu, D. F., Popescu, L. M., & Popescu, B. O. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-75 · Cited by 113
Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice
Dewachter, I., Filipkowski, R. K., Priller, C., Ris, L., Neyton, J., Croes, S., Terwel, D., Gysemans, M., Devijver, H., Borghgraef, P., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.011 · Cited by 116
Molecules that Target beta‐Amyloid
Stains, C. I., Mondal, K., & Ghosh, I. (2007) · ChemMedChem · doi:10.1002/cmdc.200700140 · Cited by 113
Synaptic Dysfunction in Alzheimer’s Disease
Marcello, E. E., Epis, R., Saraceno, C., & Luca, M. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_25 · Cited by 115
The role of amyloid β in the pathogenesis of Alzheimer's disease
Gilbert, B. J. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201515 · Cited by 109
Neuronal Structure is Altered by Amyloid Plaques
Spires‐Jones, T. L., & Hyman, B. T. (2004) · Reviews in the Neurosciences · doi:10.1515/revneuro.2004.15.4.267 · Cited by 108
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease
Klein, W. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.11.003 · Cited by 109
Self-citationBao, F., Wicklund, L., Lacor, P. N., Klein, W. L., Nordberg, A. K., & Marutle, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.003 · Cited by 112
Self-citationSpecific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Magnusson, K., Sehlin, D., Syvänen, S., Svedberg, M. M., Philipson, O., Söderberg, L., Tegerstedt, K., Holmquist, M., Gellerfors, P., Максимилианович, Т. В., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130029 · Cited by 107
Stefani, M., & Rigacci, S. (2014) · BioFactors · doi:10.1002/biof.1171 · Cited by 106
He, R., Lü, J., & Jun-Ye, M. I. A. O. (2010) · Science China Life Sciences · doi:10.1007/s11427-010-4112-3 · Cited by 105
Distinct Pools of β-Amyloid in Alzheimer Disease–Affected Brain: A Clinicopathologic Study
Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B., & Stern, Y. (2008) · Archives of Neurology · doi:10.1001/archneur.65.7.906 · Cited by 104
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease
Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103
Miñano-Molina, A. J., España, J., Martín, E., Barneda‐Zahonero, B., Fadó, R., Solé, M., Trullás, R., Saura, C. A., & Rodrı́guez-Álvarez, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227504 · Cited by 114
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 105
A Peptidomimetic Approach to Targeting Pre-amyloidogenic States in Type II Diabetes
Hebda, J. A., Saraogi, I., Magzoub, M. M., Hamilton, A. D., & Miranker, A. D. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.08.013 · Cited by 102
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers
Kim, K., Lee, C. H., & Park, C. B. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00107d · Cited by 101
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Vassar, R. J., & Cole, S. (2007) · Current Genomics · doi:10.2174/138920207783769512 · Cited by 108
The “ins” and “outs” of the high‐affinity choline transporter CHT1
Ribeiro, F. M., Black, S. A. G., Prado, V. F., Rylett, R. J., Ferguson, S. S. G., & Prado, M. A. M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03695.x · Cited by 110
Amyloid‐β oligomers are inefficiently measured by enzyme‐linked immunosorbent assay
Stenh, C., Englund, H., Lord, A., Johansson, A., Almeida, C. G., Gellerfors, P., Greengard, P., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G. (2005) · Annals of Neurology · doi:10.1002/ana.20524 · Cited by 99
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
Welzel, A. T., Maggio, J. E., Shankar, G. M., Walker, D., Ostaszewski, B. L., Li, S., Klyubin, I. V., Rowan, M. J., Seubert, P. A., Walsh, D. M., et al. (2014) · Biochemistry · doi:10.1021/bi5003053 · Cited by 102
Dutta, S., Foley, A. R., Warner, C. J. A., Zhang, X., Rolandi, M., Abrams, B. S., & Raskatov, J. A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706279 · Cited by 98
A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers
Sun, L., Zhong, Y., Gui, J., Wang, X., Zhuang, X., & Weng, J. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s152163 · Cited by 100
Metadata
- Authors
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L.
- Affiliations
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-08-18
- Volume
- 100
- Issue
- 18
- Pages
- 10417-10422
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC193576
- OpenAlex
- W2040721710
- Cited by
- 1,061
- References
- 55
- Citations by year
- 2026: 21 · 2025: 15 · 2024: 19 · 2023: 32 · 2022: 24 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 44 · 2017: 45 · 2016: 32 · 2015: 42 · 2014: 52 · 2013: 49 · 2012: 53
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Northwestern University
- National Institutes of Health (1p01ag015501-01)
- National Institute on Aging (P01-AG15501, R01-AG18877, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, memory loss, hippocampal long-term potentiation, synaptic plasticity, synaptic loss, frontal cortex, dendrites, protein-ligand binding, amyloid plaques, therapeutic vaccines
- MeSH terms
- Alzheimer Disease, Animals, Binding Sites, Brain Chemistry, Cells, Cultured, Cerebral Cortex, Ligands, Neurons, Oligopeptides, Peptide Fragments, Tissue Extracts, Immunoblotting, Amyloid beta-Peptides, Rats, Sprague-Dawley, Long-Term Potentiation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
